Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015 (Q26801010)

Francesco Luzza

13

0 references

Carlo Calabrese

Carlo Calabrese

11

0 references

Enzo Ierardi

Enzo Ierardi

8

0 references

Giovanni Maconi

Giovanni Maconi

9

0 references

Bruno Annibale

Bruno Annibale

6

0 references

Giovanni Gasbarrini

16

Giovanni Gasbarrini

0 references

Massimo Rugge

10

Massimo Rugge

0 references

Fabio Farinati

7

Fabio Farinati

0 references

Reinhold W Stockbrugger

4

Reinhold Stockbrugger

0 references

author name string

Rocco Maurizio Zagari

1

0 references

Marco Romano

2

0 references

Veronica Ojetti

3

0 references

Sergio Gullini

5

0 references

Francesco Di Mario

12

0 references

Stefano Pretolani

14

0 references

Antonella Savio

Digestive and Liver Disease

15

0 references

language of work or name

English

0 references

publication date

November 2015

0 references

published in

0 references

volume

47

0 references

page(s)

903-12

0 references

issue

11

0 references

cites work

Helicobacter pylori Eradication for Functional Dyspepsia: What Are We Treating?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

First-degree relatives of early-onset gastric cancer patients show a high risk for gastric cancer: phenotype and genotype profile

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

CagA antigen of helicobacter pylori and coronary instability: Insight from a clinico-pathological study and a meta-analysis of 4241 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Epidemiology of reflux symptoms and GORD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori infection and oesophageal cancer risk: association studies via evidence-based meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

"Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Prevalence of lesions detected at upper endoscopy: an Italian survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

When bacteria become mutagenic and carcinogenic: lessons from H. pylori

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

"Cervia Working Group Report": guidelines on the diagnosis and treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori: diseases, tests and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Genetics of gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Proton pump inhibitors and risk of gastric cancer: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Changing Patterns of Helicobacter pylori Gastritis in Long-Standing Acid Suppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portu

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Are guidelines followed in Helicobacter pylori diagnosis and therapy? An inquiry among gastroenterologists, referring physicians and patients in Munich

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

In-vitro activity of lansoprazole against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Epidemiology of Helicobacter pylori in Bhutan: the role of environment and Geographic location.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Epidemiology of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Accuracy of Monoclonal Stool Tests for Determining Cure of Helicobacter pylori Infection After Treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori Infection, Intestinal Metaplasia, and Gastric Cancer Risk in Eastern Siberia

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Effects of Helicobacter pylori eradication on gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Micronutrients (Other than iron) and Helicobacter pylori infection: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Investigating dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Guidelines for the management of iron deficiency anaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Occupational exposures and risk of stomach cancer by histological type

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Iron deficiency anaemia can be improved after eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association).

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Eradication of Helicobacter pylori infection: which regimen first?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021

Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.DLD.2015.06.010

7 January 2021